Microribonucleic acids for prevention of plaque rupture and in-stent restenosis: "a finger in the dam"

Journal of the American College of Cardiology

Volumn 57, Issue 4, 2011, Pages 383-389

  O'Sullivan, John F ^a   Martin, Kenneth ^a   Caplice, Noel M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

CArG; CC(A T)6GG; in stent restenosis; ISR; messenger ribonucleic acid; micro ribonucleic acid; miRNA; mRNA; PDGF; platelet derived growth factor; vascular smooth muscle cell; VSMC

Indexed keywords

ADENOVIRUS VECTOR; ANTAGOMIR; CALPONIN; CHEMOKINE RECEPTOR CXCR4; DICER; DROSHA; E2F DECOY OLIGONUCLEOTIDE; ENDONUCLEASE; FIBROBLAST GROWTH FACTOR; GENE THERAPY AGENT; INTEGRIN; KRUPPEL LIKE FACTOR 4; MICRORNA; MICRORNA 143; MICRORNA 145; MICRORNA 21; MICRORNA 221; MYOCARDIN; OLIGODEOXYNUCLEOTIDE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SMOOTHELIN; THROMBOXANE A2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANGINA PECTORIS; ANGIOGENIC GENE THERAPY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL DIFFERENTIATION; CELL PROLIFERATION; EXTRACELLULAR MATRIX; FOCAL ADHESION; GENE CLUSTER; HEART CATHETERIZATION; HUMAN; HYPERPLASIA; IN-STENT RESTENOSIS; MUSCLE DEVELOPMENT; NEOINTIMA; NEOINTIMAL HYPERPLASIA; PRIORITY JOURNAL; RNA TRANSLATION; ROUGH ENDOPLASMIC RETICULUM; SMOOTH MUSCLE FIBER; STENT; VASCULAR SMOOTH MUSCLE;

EID: 78751637010     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.09.029     Document Type: Review

References (85)

1. Y. Zhao, and D. Srivastava A developmental view of microRNA function Trends Biochem Sci 32 2007 189 197
2. W.P. Kloosterman, and R.H. Plasterk The diverse functions of microRNAs in animal development and disease Dev Cell 11 2006 441 450
3. G.A. Calin, and C.M. Croce MicroRNA signatures in human cancers Nat Rev Cancer 6 2006 857 866
4. R.C. Friedman, K.K. Farh, C.B. Burge, and D.P. Bartel Most mammalian mRNAs are conserved targets of microRNAs Genome Res 19 2009 92 105
5. S.Y. Ying, and S.L. Lin Intronic microRNAs Biochem Biophys Res Commun 326 2005 515 520
6. S. Baskerville, and D.P. Bartel Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes RNA 11 2005 241 247
7. Y. Lee, M. Kim, and J. Han MicroRNA genes are transcribed by RNA polymerase II EMBO J 23 2004 4051 4060
8. Y. Altuvia, P. Landgraf, and G. Lithwick Clustering and conservation patterns of human microRNAs Nucleic Acids Res 33 2005 2697 2706
9. D.P. Bartel MicroRNAs: genomics, biogenesis, mechanism, and function Cell 116 2004 281 297
10. S.M. Hammond, S. Boettcher, A.A. Caudy, R. Kobayashi, and G.J. Hannon Argonaute2, a link between genetic and biochemical analyses of RNAi Science 293 2001 1146 1150
11. T. Boettger, N. Beetz, and S. Kostin Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster J Clin Invest 119 2009 2634 2647
12. K.R. Cordes, N.T. Sheehy, and M.P. White miR-145 and miR-143 regulate smooth muscle cell fate and plasticity Nature 460 2009 705 710
13. Y. Cheng, X. Liu, and J. Yang MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation Circ Res 105 2009 158 166
14. L. Elia, M. Quintavalle, and J. Zhang The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease Cell Death Differ 16 2009 1590 1598
15. S. Kim, H.S. Ip, M.M. Lu, C. Clendenin, and M.S. Parmacek A serum response factor-dependent transcriptional regulatory program identifies distinct smooth muscle cell sublineages Mol Cell Biol 17 1997 2266 2278
16. L. Li, J.M. Miano, P. Cserjesi, and E.N. Olson SM22 alpha, a marker of adult smooth muscle, is expressed in multiple myogenic lineages during embryogenesis Circ Res 78 1996 188 195
17. C.P. Mack, and G.K. Owens Regulation of smooth muscle alpha-actin expression in vivo is dependent on CArG elements within the 5' and first intron promoter regions Circ Res 84 1999 852 861
18. I. Manabe, and G.K. Owens The smooth muscle myosin heavy chain gene exhibits smooth muscle subtype-selective modular regulation in vivo J Biol Chem 276 2001 39076 39087
19. M. Mericskay, A. Parlakian, and A. Porteu An overlapping CArG/octamer element is required for regulation of desmin gene transcription in arterial smooth muscle cells Dev Biol 226 2000 192 208
20. J.M. Miano Serum response factor: toggling between disparate programs of gene expression J Mol Cell Cardiol 35 2003 577 593
21. H. Yano, K. Hayashi, T. Momiyama, H. Saga, M. Haruna, and K. Sobue Transcriptional regulation of the chicken caldesmon gene Activation of gizzard-type caldesmon promoter requires a CArG box-like motif J Biol Chem 270 1995 23661 23666
22. D. Wang, P.S. Chang, and Z. Wang Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor Cell 105 2001 851 862
23. T. Yoshida, S. Sinha, and F. Dandre Myocardin is a key regulator of CArG-dependent transcription of multiple smooth muscle marker genes Circ Res 92 2003 856 864
24. X. Long, R.D. Bell, W.T. Gerthoffer, B.V. Zlokovic, and J.M. Miano Myocardin is sufficient for a smooth muscle-like contractile phenotype Arterioscler Thromb Vasc Biol 28 2008 1505 1510
25. M. Clarke, and M. Bennett Defining the role of vascular smooth muscle cell apoptosis in atherosclerosis Cell Cycle 5 2006 2329 2331
26. P.L. Weissberg, G.J. Clesham, and M.R. Bennett Is vascular smooth muscle cell proliferation beneficial? Lancet 347 1996 305 307
27. M.J. Davies The composition of coronary-artery plaques N Engl J Med 336 1997 1312 1314
28. F.D. Kolodgie, A.P. Burke, and A. Farb The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes Curr Opin Cardiol 16 2001 285 292
29. I.J. Kullo, W.D. Edwards, and R.S. Schwartz Vulnerable plaque: pathobiology and clinical implications Ann Intern Med 129 1998 1050 1060
30. G.K. Owens Regulation of differentiation of vascular smooth muscle cells Physiol Rev 75 1995 487 517
31. R. Ross The pathogenesis of atherosclerosisan update N Engl J Med 314 1986 488 500
32. Z.S. Galis, and J.J. Khatri Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly Circ Res 90 2002 251 262
33. Z.S. Galis, G.K. Sukhova, M.W. Lark, and P. Libby Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques J Clin Invest 94 1994 2493 2503
34. G. Liau, J.A. Winkles, M.S. Cannon, L. Kuo, and W.M. Chilian Dietary-induced atherosclerotic lesions have increased levels of acidic FGF mRNA and altered cytoskeletal and extracellular matrix mRNA expression J Vasc Res 30 1993 327 332
35. E.M. Tan, E. Glassberg, and D.R. Olsen Extracellular matrix gene expression by human endothelial and smooth muscle cells Matrix 11 1991 380 387
36. E.A. Turley Extracellular matrix remodeling: multiple paradigms in vascular disease Circ Res 88 2001 2 4
37. G.K. Hansson, L. Jonasson, J. Holm, and L. Claesson-Welsh Class II MHC antigen expression in the atherosclerotic plaque: smooth muscle cells express HLA-DR, HLA-DQ and the invariant gamma chain Clin Exp Immunol 64 1986 261 268
38. J.X. Rong, J.W. Berman, M.B. Taubman, and E.A. Fisher Lysophosphatidylcholine stimulates monocyte chemoattractant protein-1 gene expression in rat aortic smooth muscle cells Arterioscler Thromb Vasc Biol 22 2002 1617 1623
39. M. Roque, W.J. Kim, and M. Gazdoin CCR2 deficiency decreases intimal hyperplasia after arterial injury Arterioscler Thromb Vasc Biol 22 2002 554 559
40. O. Kocher, and G. Gabbiani Cytoskeletal features of normal and atheromatous human arterial smooth muscle cells Hum Pathol 17 1986 875 880
41. O. Kocher, F. Gabbiani, and G. Gabbiani Phenotypic features of smooth muscle cells during the evolution of experimental carotid artery intimal thickening Biochemical and morphologic studies Lab Invest 65 1991 459 470
42. N. Malik, S.E. Francis, and C.M. Holt Apoptosis and cell proliferation after porcine coronary angioplasty Circulation 98 1998 1657 1665
43. A. Lopez-Candales, D.R. Holmes, S. Liao, M.J. Scott, S.A. Wickline, and R.W. Thompson Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms Am J Pathol 150 1997 993 1007
44. E. Lutgens, E.D. de Muinck, P.J. Kitslaar, J.H. Tordoir, H.J. Wellens, and M.J. Daemen Biphasic pattern of cell turnover characterizes the progression from fatty streaks to ruptured human atherosclerotic plaques Cardiovasc Res 41 1999 473 479
45. Y.J. Geng, and P. Libby Evidence for apoptosis in advanced human atheroma Colocalization with interleukin-1 beta-converting enzyme Am J Pathol 147 1995 251 266
46. G.K. Owens, M.S. Kumar, and B.R. Wamhoff Molecular regulation of vascular smooth muscle cell differentiation in development and disease Physiol Rev 84 2004 767 801
47. A. Zernecke, K. Bidzhekov, and H. Noels Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection Sci Signal 2 2009 ra81
48. A.K. Mitra, and D.K. Agrawal In stent restenosis: bane of the stent era J Clin Pathol 59 2006 232 239
49. J.M. Isner, M. Kearney, S. Bortman, and J. Passeri Apoptosis in human atherosclerosis and restenosis Circulation 91 1995 2703 2711
50. E.W. Raines PDGF and cardiovascular disease Cytokine Growth Factor Rev 15 2004 237 254
51. D.A. Jones, C.W. Benjamin, and D.A. Linseman Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades Mol Pharmacol 48 1995 890 896
52. R. Gallo, A. Padurean, and V. Toschi Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries Circulation 97 1998 581 588
53. W.J. Tanski, E. Roztocil, E.A. Hemady, J.A. Williams, and M.G. Davies Role of Gαq in smooth muscle cell proliferation J Vasc Surg 39 2004 639 644
54. R. Komatsu, M. Ueda, T. Naruko, A. Kojima, and A.E. Becker Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses Circulation 98 1998 224 233
55. E. Millette, B.H. Rauch, O. Defawe, R.D. Kenagy, G. Daum, and A.W. Clowes Platelet-derived growth factor-BB-induced human smooth muscle cell proliferation depends on basic FGF release and FGFR-1 activation Circ Res 96 2005 172 179
56. A. Farb, F.D. Kolodgie, and J.-Y. Hwang Extracellular matrix changes in stented human coronary arteries Circulation 110 2004 940 947
57. A. Schmidt, S. Lorkowski, D. Seidler, G. Breithardt, and E. Buddecke TGF-beta generates a specific multicomponent extracellular matrix in human coronary SMC Eur J Clin Invest 36 2006 473 482
58. R. Ji, Y. Cheng, and J. Yue MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation Circ Res 100 2007 1579 1588
59. T. Thum, C. Gross, and J. Fiedler MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts Nature 456 2008 980 984
60. F. Fleissner, V. Jazbutyte, and J. Fiedler Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism Circ Res 107 2010 138 143
61. B.N. Davis, A.C. Hilyard, P.H. Nguyen, G. Lagna, and A. Hata Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype J Biol Chem 284 2009 3728 3738
62. R. Gupta, J. Tongers, and D.W. Losordo Human studies of angiogenic gene therapy Circ Res 2009 724 736
63. C.L. Grines, M.W. Watkins, and G. Helmer Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris Circulation 105 2002 1291 1297
64. T.D. Henry, C.L. Grines, and M.W. Watkins Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials J Am Coll Cardiol 2007 1038 1046
65. C.L. Grines, M.W. Watkins, J.J. Mahmarian AGENT 2 Study Group A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina J Am Coll Cardiol 2003 1339 1347
66. M. Hedman, J. Hartikainen, and M. Syvanne Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT) Circulation 107 2003 2677 2683
67. J. Weiler, J. Hunziker, and J. Hall Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther 13 2006 496 502
68. J. Krutzfeldt, N. Rajewsky, and R. Braich Silencing of microRNAs in vivo with 'antagomirs ' Nature 438 2005 685 689
69. Z. Lin, I. Murtaza, K. Wang, J. Jiao, J. Gao, and P.F. Li miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy Proc Natl Acad Sci U S A 106 2009 12103 12108
70. A. Care, D. Catalucci, and F. Felicetti MicroRNA-133 controls cardiac hypertrophy Nat Med 13 2007 613 618
71. X.P. Ren, J. Wu, and X. Wang MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20 Circulation 119 2009 2357 2366
72. E. van Rooij, L.B. Sutherland, and J.E. Thatcher Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis Proc Natl Acad Sci U S A 105 2008 13027 13032
73. A. Bonauer, G. Carmona, and M. Iwasaki MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice Science 324 2009 1710 1713
74. D.J. Stewart, J.D. Hilton, and J.M. Arnold Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment Gene Ther 13 2006 1503 1511
75. D.A. Dean Nonviral gene transfer to skeletal, smooth, and cardiac muscle in living animals Am J Physiol Cell Physiol 289 2005 C233 C245
76. D.B. Rozema, D.L. Lewis, and D.H. Wakefield Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes Proc Natl Acad Sci U S A 104 2007 12982 12987
77. M.J. Mann, and V.J. Dzau Therapeutic applications of transcription factor decoy oligonucleotides J Clin Invest 106 2000 1071 1075
78. V.J. Dzau, M.J. Mann, R. Morishita, and Y. Kaneda Fusigenic viral liposome for gene therapy in cardiovascular diseases Proc Natl Acad Sci U S A 93 1996 11421 11425
79. M.J. Mann, A.D. Whittemore, and M.C. Donaldson Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial Lancet 354 1999 1493 1498
80. M.V. Iorio, M. Ferracin, and C.G. Liu MicroRNA gene expression deregulation in human breast cancer Cancer Res 65 2005 7065 7070
81. M.Z. Michael, S.M. O'Connor, N.G. van Holst Pellekaan, G.P. Young, and R.J. James Reduced accumulation of specific microRNAs in colorectal neoplasia Mol Cancer Res 1 2003 882 891
82. M. Sachdeva, S. Zhu, and F. Wu p53 represses c-Myc through induction of the tumor suppressor miR-145 Proc Natl Acad Sci U S A 106 2009 3207 3212
83. M. Crawford, E. Brawner, and K. Batte MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines Biochem Biophys Res Commun 373 2008 607 612
84. H. He, K. Jazdzewski, and W. Li The role of microRNA genes in papillary thyroid carcinoma Proc Natl Acad Sci U S A 102 2005 19075 19080
85. A. Conti, M. Aguennouz, and D. La Torre miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors J Neurooncol 93 2009 325 332